Főoldal » Tudomány » Szendi Gábor: Demencia – nincs visszaút?

Szendi Gábor: Demencia – nincs visszaút?

<< Folytatás az előző oldalról

Szakirodalmi hivatkozások

  1. Alzheimer’s Association, 2014 Alzheimer’s Disease Facts and Figures, Alzheimer’s & Dementia, Volume 10, Issue 2.
  2. O’Connor, DW: Epidemiology. in: Burns, A; O’Brien, J; Ames, D (eds.): Dementia. Hodder Arnold, London, 2005. Third ed. pp:16-23.
  3. Sadik K, Wilcock G. The increasing burden of Alzheimer disease. Alzheimer Dis Assoc Disord. 2003 Jul-Sep;17 Suppl 3:S75-9.
  4. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002 Jul 19;297(5580):353-6.
  5. Morris, JC: Persistent Failure of “Disease-Modifying” Drugs to Benefit Alzheimer Disease: Now What? The DANA Foundation, July 10, 2013. web: http://www.dana.org/publications/Persistent_Failure_of_DiseaseModifying_ Drugs_to_Benefit_Alzheimer_Disease__Now_What_/
  6. Mondragón-Rodríguez S, Basurto-Islas G, Lee HG, Perry G, Zhu X, Castellani RJ, Smith MA. Causes versus effects: the increasing complexities of Alzheimer’s disease pathogenesis. Expert Rev Neurother. 2010, 10(5):683-91.
  7. Raber J, Huang Y, Ashford JW. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging. 2004 May-Jun;25(5):641-50.
  8. Henderson ST. High carbohydrate diets and Alzheimer’s disease. Med Hypotheses. 2004;62(5):689-700.
  9. Corbo RM, Scacchi R. Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a ‘thrifty’ allele? Ann Hum Genet. 1999 Jul;63(Pt 4):301-10.
  10. Hendrie HC, Hall KS, Pillay N, Rodgers D, Prince C, Norton J, Brittain H, Nath A, Blue A, Kaufert J, et al. Alzheimer’s disease is rare in Cree. Int Psychogeriatr. 1993 Spring;5(1):5-14.
  11. Gureje O, Ogunniyi A, Baiyewu O, Price B, Unverzagt FW, Evans RM, Smith-Gamble V, Lane KA, Gao S, Hall KS, Hendrie HC, Murrell JR. APOE epsilon4 is not associated with Alzheimer’s disease in elderly Nigerians. Ann Neurol. 2006 Jan;59(1):182-5.
  12. Grant, WB: Incidence of Dementia and Alzheimer Disease in Nigeria and the United States. JAMA 2001;285:739-47
  13. Peila R, Rodriguez BL, Launer LJ; Honolulu-Asia Aging Study. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes. 2002 Apr;51(4):1256-62.
  14. White L, Petrovitch H, Ross GW, Masaki KH, Abbott RD, Teng EL, Rodriguez BL, Blanchette PL, Havlik RJ, Wergowske G, Chiu D, Foley DJ, Murdaugh C, Curb JD. Prevalence of dementia in older Japanese-American men in Hawaii: The Honolulu-Asia Aging Study. JAMA. 1996 Sep 25;276(12):955-60.
  15. Matsuzaki T, Sasaki K, Tanizaki Y, Hata J, Fujimi K, Matsui Y, Sekita A, Suzuki SO, Kanba S, Kiyohara Y, Iwaki T. Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. Neurology. 2010 Aug 31;75(9):764-70.
  16. Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP, Yaffe K. Central obesity and increased risk of dementia more than three decades later. Neurology. 2008 Sep 30;71(14):1057-64.
  17. Crane PK, Walker R, Hubbard RA, Li G, Nathan DM, Zheng H, Haneuse S, Craft S, Montine TJ, Kahn SE, McCormick W, McCurry SM, Bowen JD, Larson EB. Glucose levels and risk of dementia. N Engl J Med. 2013 Aug 8;369(6):540-8.
  18. de la Monte SM, Wands JR. Alzheimer’s disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol. 2008 Nov;2(6):1101-13.
  19. Henderson ST. High carbohydrate diets and Alzheimer’s disease. Med Hypotheses. 2004;62(5):689-700.
  20. Van der Auwera I, Wera S, Van Leuven F, Henderson ST. A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer’s disease. Nutr Metab (Lond). 2005 Oct 17;2:28.
  21. Scarmeas N, Stern Y, Mayeux R, Luchsinger JA. Mediterranean diet, Alzheimer disease, and vascular mediation. Arch Neurol. 2006 Dec;63(12):1709-17.
  22. Bredesen DE. Reversal of cognitive decline: a novel therapeutic program. Aging (Albany NY). 2014 Sep;6(9):707-17.
  23. Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer’s disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond). 2009 Aug 10;6:31.
  24. Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol. 2002 Aug;52(2):168-74.
  25. Tobinick E. Perispinal etanercept for treatment of Alzheimer’s disease. Curr Alzheimer Res. 2007 Dec;4(5):550-2.
  26. Cherniack EP, Troen BR, Florez HJ, Roos BA, Levis S. Some new food for thought: the role of vitamin D in the mental health of older adults. Curr Psychiatry Rep. 2009 Feb;11(1):12-9.
  27. Shen L, Ji HF. Vitamin D deficiency is associated with increased risk of Alzheimer’s disease and dementia: evidence from meta-analysis. Nutr J. 2015 Aug 1;14:76.
  28. Cunnane SC, Plourde M, Pifferi F, Bégin M, Féart C, Barberger-Gateau P. Fish, docosahexaenoic acid and Alzheimer’s disease. Prog Lipid Res. 2009 Sep;48(5):239-56.
  29. Morris MC. The role of nutrition in Alzheimer’s disease: epidemiological evidence. Eur J Neurol. 2009 Sep;16 Suppl 1:1-7.
  30. Ravaglia G, Forti P, Maioli F, Martelli M, Servadei L, Brunetti N, Porcellini E, Licastro F. Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am J Clin Nutr. 2005 Sep;82(3):636-43.
  31. Hooshmand B, Solomon A, Kareholt I, Leiviskä J, Rusanen M, Ahtiluoto S, Winblad B, Laatikainen T, Soininen H, Kivipelto M. Homocysteine and holotranscobalamin and the risk of Alzheimer disease: a longitudinal study. Neurology. 2010 Oct 19;75(16):1408-14.
  32. Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, Love S, Schellenberg GD, McCarten JR, Malphurs J, Prieto S, Chen P, Loreck DJ, Trapp G, Bakshi RS, Mintzer JE, Heidebrink JL, Vidal-Cardona A, Arroyo LM, Cruz AR, Zachariah S, Kowall NW, Chopra MP, Craft S, Thielke S, Turvey CL, Woodman C, Monnell KA, Gordon K, Tomaska J, Segal Y, Peduzzi PN, Guarino PD. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA. 2014 Jan 1;311(1):33-44.
  33. Dietschy JM, Turley SD. Cholesterol metabolism in the brain. Curr Opin Lipidol 2001;12:105-12.
  34. Sjögren M, Blennow K. The link between cholesterol and Alzheimer’s disease. World J Biol Psychiatry. 2005;6(2):85-97.
  35. Swiger KJ, Manalac RJ, Blumenthal RS, Blaha MJ, Martin SS. Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects. Mayo Clin Proc. 2013 Nov;88(11):1213-21.
  36. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy. 2003 Jul;23(7):871-80.
  37. Golomb BA, Evans MA. Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008;8(6):373-418.
  38. Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, Tuomilehto J, Nissinen A. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer’s disease. Neuroepidemiology. 1998;17(1):14-20.
  39. Mielke MM, Zandi PP, Sjögren M, Gustafson D, Ostling S, Steen B, Skoog I. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology. 2005 May 24;64(10):1689-95.
  40. West R, Beeri MS, Schmeidler J, Hannigan CM, Angelo G, Grossman HT, Rosendorff C, Silverman JM. Better memory functioning associated with higher total and low-density lipoprotein cholesterol levels in very elderly subjects without the apolipoprotein e4 allele. Am J Geriatr Psychiatry. 2008 Sep;16(9):781-5.
  41. Mielke MM, Zandi PP, Shao H, Waern M, Östling S, Guo X, Björkelund C, Lissner L, Skoog I, Gustafson DR. The 32-year relationship between cholesterol and dementia from midlife to late life. Neurology. 2010 Nov 23;75(21):1888-95.
  42. Eskelinen MH, Ngandu T, Tuomilehto J, Soininen H, Kivipelto M. Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study. J Alzheimers Dis. 2009;16(1):85-91.
  43. Lindsay J, Laurin D, Verreault R, Hébert R, Helliwell B, Hill GB, McDowell I. Risk factors for Alzheimer’s disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol. 2002 Sep 1;156(5):445-53.
  44. Carman AJ, Dacks PA, Lane RF, Shineman DW, Fillit HM. Current evidence for the use of coffee and caffeine to prevent age-related cognitive decline and Alzheimer’s disease. J Nutr Health Aging. 2014 Apr;18(4):383-92.
  45. Cao C, Loewenstein DA, Lin X, Zhang C, Wang L, Duara R, Wu Y, Giannini A, Bai G, Cai J, Greig M, Schofield E, Ashok R, Small B, Potter H, Arendash GW. High Blood caffeine levels in MCI linked to lack of progression to dementia. J Alzheimers Dis. 2012;30(3):559-72.
  46. Szendi G: Boldogtalanság és evolúció. Jaffa, Bp., 2011.
  47. Radak Z, Hart N, Sarga L, Koltai E, Atalay M, Ohno H, Boldogh I. Exercise plays a preventive role against Alzheimer’s disease. J Alzheimers Dis. 2010;20(3):777-83.
  48. Newington JT, Harris RA, Cumming RC. Reevaluating Metabolism in Alzheimer’s Disease from the Perspective of the Astrocyte-Neuron Lactate Shuttle Model. J Neurodegener Dis. 2013;2013:234572.
  49. M. Roig, K. Skriver, J. Lundbye-Jensen, B. Kiens, and J. B. Nielsen, A single bout of exercise improves motor memory. PLoS ONE, vol. 7, no. 9,
  50. A. S. Buchman, P. A. Boyle, L. Yu, R. C. Shah, R. S.Wilson, and D. A. Bennett, Total daily physical activity and the risk of AD and cognitive decline in older adults. Neurology, vol. 79, no. 10, p. 1071, 2012.
  51. N. Scarmeas, J. A. Luchsinger,N. Schupf et al., Physical activity, diet, and risk of Alzheimer disease, The Journal of the American Medical Association, vol. 302, no. 6, pp. 627-637, 2009.
  52. Blázquez E, Velázquez E, Hurtado-Carneiro V, Ruiz-Albusac JM. Insulin in the brain: its pathophysiological implications for States related with central insulin resistance, type 2 diabetes and Alzheimer’s disease. Front Endocrinol (Lausanne). 2014 Oct 9;5:161.
  53. Ott V,Benedict C,Schultes B,Born J,Hallschmid M: Intranasal administration of insulin to the brain impacts cognitive function and peripheral metabolism. Diabetes ObesMetab (2012) 14(3):214-21.
  54. Guzmán M, Blázquez C. Ketone body synthesis in the brain: possible neuroprotective effects. Prostaglandins Leukot Essent Fatty Acids. 2004 Mar;70(3):287-92.
  55. Krikorian R, Shidler MD, Dangelo K, Couch SC, Benoit SC, Clegg DJ. Dietary ketosis enhances memory in mild cognitive impairment. Neurobiol Aging. 2012 Feb;33(2):425.e19-27.
  56. Paoli A, Bianco A, Damiani E, Bosco G. Ketogenic diet in neuromuscular and neurodegenerative diseases. Biomed Res Int. 2014;2014:474296.
  57. Cunnane S, Nugent S, Roy M, Courchesne-Loyer A, Croteau E, Tremblay S, Castellano A, Pifferi F, Bocti C, Paquet N, Begdouri H, Bentourkia M, Turcotte E, Allard M, Barberger-Gateau P, Fulop T, Rapoport SI. Brain fuel metabolism, aging, and Alzheimer’s disease. Nutrition. 2011 Jan;27(1):3-20.

Szerzőnk: Szendi Gábor

Szendi Gábor

Weboldalunk sütiket (cookie-kat) használ a jobb és biztonságosabb működés érdekében. A böngészés folytatásával jóváhagyja a cookie-k használatát. További információk

Kedves látogatónk!
A cookie-k, vagy sütik kis adatfájlok, amelyeket a böngésző helyez el a felhasználó számítógépén, vagy eszközén. A weboldalak így olyan információkat képesek tárolni, amelyek hatékonyabbá és kellemesebbé teszik a böngészést.
Weboldalunk is ilyen sütiket használ a jobb és biztonságosabb működés érdekében. Ezek a sütik nem tárolnak személyes adatokat.
A sütiket Ön bármikor törölheti a böngészőjében, vagy akár beállíthatja a sütik teljes elutasítását is, ez esetben viszont nem garantált a honlap hibátlan működése.

Bezárás